Solventum Corporation $SOLV Shares Purchased by Davis Selected Advisers

Davis Selected Advisers increased its position in shares of Solventum Corporation (NYSE:SOLV) by 0.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,517,611 shares of the company’s stock after buying an additional 24,950 shares during the period. Solventum accounts for 2.1% of Davis Selected Advisers’ holdings, making the stock its 17th biggest position. Davis Selected Advisers owned about 3.18% of Solventum worth $402,786,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SOLV. Clifford Capital Partners LLC increased its stake in shares of Solventum by 3.1% in the 2nd quarter. Clifford Capital Partners LLC now owns 269,790 shares of the company’s stock valued at $20,461,000 after purchasing an additional 8,085 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. boosted its position in Solventum by 103.0% during the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 6,029 shares of the company’s stock worth $457,000 after purchasing an additional 3,059 shares in the last quarter. Nordea Investment Management AB boosted its position in Solventum by 3.5% during the third quarter. Nordea Investment Management AB now owns 758,847 shares of the company’s stock worth $54,880,000 after purchasing an additional 25,987 shares in the last quarter. LSV Asset Management grew its holdings in Solventum by 364.5% in the third quarter. LSV Asset Management now owns 35,122 shares of the company’s stock valued at $2,564,000 after purchasing an additional 27,561 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Solventum by 15.3% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock valued at $22,469,000 after purchasing an additional 40,812 shares during the period.

Insider Transactions at Solventum

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

SOLV has been the subject of several research analyst reports. Wells Fargo & Company reduced their target price on Solventum from $86.00 to $83.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th. BTIG Research reissued a “buy” rating and issued a $100.00 price target on shares of Solventum in a research note on Friday, February 27th. KeyCorp boosted their price target on shares of Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Mizuho set a $100.00 price objective on shares of Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Finally, Zacks Research downgraded shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Seven investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Solventum currently has a consensus rating of “Moderate Buy” and an average target price of $93.70.

Solventum Stock Performance

NYSE SOLV opened at $67.18 on Thursday. The company has a market cap of $11.66 billion, a PE ratio of 7.57, a price-to-earnings-growth ratio of 1.13 and a beta of 0.40. The stock’s 50 day simple moving average is $75.50 and its 200-day simple moving average is $75.88. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $88.20. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. During the same period in the previous year, the company posted $1.41 earnings per share. The business’s revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, equities research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum declared that its board has authorized a share repurchase program on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.